Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials
Cancer Treatment Reviews · 2025-11 · 140 · 103002
DOI: 10.1016/j.ctrv.2025.103002 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Treatment Reviews, 2025-11. Verfasst von Joseph J Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National University Hospital, Singapore, Singapore; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore;…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Immune Checkpoint Inhibitors, Stomach Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: National University of Singapore, National Institutes of Health, SingHealth.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, National University Hospital, Singapore, Singapore; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Si…
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore.
- Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
- Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sklempner@mgb.org.
Förderung
- National University of Singapore
- National Institutes of Health
- SingHealth
- Dana-Farber/Harvard Cancer Center
- Government of Singapore Ministry of Health
- National Medical Research Council
- Dana Foundation
- National University Health System
Zitieren
APA
Zhao, J. J., Yi Ng, K. Y., Sundar, R., & Klempner, S. J. (2025). Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials. Cancer Treatment Reviews, 140, 103002. https://doi.org/10.1016/j.ctrv.2025.103002
Vancouver
Zhao JJ, Yi Ng KY, Sundar R, Klempner SJ. Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials. Cancer Treatment Reviews. 2025;140:103002. doi:10.1016/j.ctrv.2025.103002
BibTeX
@article{Zhao2025,
author = {Zhao, Joseph J and Yi Ng, Kennedy Yao and Sundar, Raghav and Klempner, Samuel J},
title = {Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials},
journal = {Cancer Treatment Reviews},
year = {2025},
volume = {140},
pages = {103002},
doi = {10.1016/j.ctrv.2025.103002}
}
EUVIMED